biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01
TRANSCRIPT
![Page 1: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/1.jpg)
Presented by:
Ms. Suruchi Ramkumar Sharma
F.Y. M.Pharm
Under the guidance of:
Dr. (Mrs.) Vaishali Dixit
M.E.T Institute of Pharmacy, Bandra (W)
12-Mar-2012
![Page 2: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/2.jpg)
Definition:
The US FDA defines a biomarker as a characteristic i.e.
objectively measured & evaluated as an indicator of
normal biologic, pathogenic or pharmacologic responses to therapeutic
intervention.2
![Page 3: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/3.jpg)
• It can be specific cells, molecules or genes, gene products, enzymes or hormones.
• Helps in early diagnosis, disease prevention, drug target identification, drug response etc.
Examples• serum LDL for cholesterol • blood pressure for stroke• C-reactive protein (CRP) for inflammation
3
![Page 4: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/4.jpg)
4
![Page 5: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/5.jpg)
Disease – related Biomarkers
Drug – related Biomarkers
Risk indicator / predictive biomarkers
Indicate effectiveness of a drug in a specific
patient
Diagnostic & prognostic biomarker
How the patient’s body will process it
5
![Page 6: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/6.jpg)
6
![Page 7: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/7.jpg)
7
![Page 8: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/8.jpg)
Based on Characteristics
8
![Page 9: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/9.jpg)
9
![Page 10: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/10.jpg)
Biomarkers validated by genetic and molecular biology methods can be classified into three types:
Type 0 - Natural history markers
Type 1 - Drug activity markers
Type 2 - Surrogate markers
10
![Page 11: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/11.jpg)
Discovery of
Molecular Biomarkers
ASSAY TECHNIQUES 11
![Page 12: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/12.jpg)
In Toxicology & Clinical trials -
• In vivo monitoring
• Early detection of metabolic changes
• Detection of organ‐specific effects
• Establishment of “NO EFFECT” level
• Determination of toxic mechanism
12
![Page 13: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/13.jpg)
Important issues to remember:
• Cell types differ in susceptibility to toxic agents
• One organ – many cell types
• Cellular injury vs. organ function impairment
• Oxygen concentration gradients
• Metabolizing enzymes (e.g., Cytochrome P450) concentration gradients
13
![Page 14: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/14.jpg)
Localization of damage:
Centrilobular (zone 3)• Most hepatotoxicants (CCl4, APAP)• Less oxygen + high P450 conc.
Periportal (zone 1)• Phosphorus, aflatoxin, allyl alcohol• High oxygen + highest dose at site
Midzonal (zone 2) –• Beryllium• Massive necrosis - iproniazid, MAOI
Liver Lobule
14
![Page 15: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/15.jpg)
Cholestatic injury Cytotoxic injury Altered hepatic function
Alkaline Phosphatase [AP, ALP]
Aspartate aminotransferase [AST]
Creatine phosphokinase [CPK]
5’‐Nucleotidase [5-NT]
Lactate Dehydrogenase [LDH]
Choline Esterase [ChE](acetylcholine esterase and butyrylcholine esterase)
γ - Glutamyl Transpeptidase [GGT]
Alanine aminotransferase [ALT]
Total Serum Bile Acids
Ornithine carbamyl transferase [OCT]
Decreased dye clearance •Sulfobromophthalein•Indocyanine green
Plasma Bilirubin Alanine aminotransferase [SDH]
15
![Page 16: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/16.jpg)
16
![Page 17: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/17.jpg)
Serum Indicators Urine Indicators
Blood Urea Nitrogen (BUN)
Physical characteristics
Chemical Characteristics
Blood Creatinine Color/turbidity (RBC’s, bilirubin)
Urinary protein –tubular (low MW) or glomerular (high MW)
Volume Urinary glucose –no elevation of blood glucose but glucosuria (tubular)
Osmolality Urinary brush border enzymes (ALP, AST, GGT)
17
![Page 18: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/18.jpg)
Develop new biomarkers that predict toxicity in the preclinical development of NCEs early in the drug development process and are translatable to the clinic.
To reduce the time and cost associated with drug discovery and approval.
Metabolic profiling methods used are based on metabolomics and/ or metabonomics.
Metabolomics is especially important in the early ADME/Tox stage of drug testing.
18
![Page 19: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/19.jpg)
19
![Page 20: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/20.jpg)
Acetaminophen (APAP) is responsible for 50% of all drug-induced acute liver failure.
• High-throughput LC/MS-based metabolomic assays rapidly investigate APAP and its metabolites excretion profile in urine from rats.
• Biomarker : Changes in the SAMe concentrations inversely proportional with urinary APAP–NAC concentration.20
![Page 21: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/21.jpg)
NMR-based approach to investigate toxicity induced by Bay41-4109, an anti-hepatitis B virus compound.
• Biomarker : Fatty acid metabolism disorder and mitochondrial dysfunction.
GC/MS was used to study carbon tetrachloride-induced acute liver injury in mice.
• Biomarker : Elevated levels of maleate and several fatty acids in the liver.
21
![Page 22: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/22.jpg)
UPLC/MS to investigate toxicity by CCl4 and α-napthylisothiocyanate.
• Biomarker : Changes in bile acids.
Integration of OMICS:• Metabolomics + transcriptomics liver
samples of two mouse strains regulated glutamate and glutamine networks diabetes and obesity.
• Metabolomic + proteomics liver samples of CD1 mice acute hepatotoxicity induced by valproic acid altered glucose levels.
22
![Page 23: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/23.jpg)
NMR and HPLC-TOF/MS approach for Cyclosporin A in a rodent model.
• Biomarker : Elevated levels of urinary glucose, acetate, trimethylamine, succinate and reduced levels of urinary TMAO + decreased levels of kynurenic acid, xanthurenic acid, citric acid and riboflavin.
• Biomarker : Increased levels of glucose, hydroxybutyrate, creatine, creatinine, TMAO and decreased concentration of glutathione.
23
![Page 24: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/24.jpg)
Gentamicin in SD rats,
• Biomarker : Increased urinary level of glucose and decreased level of TMAO by NMR with decreases in xanthurenic and kynurenic acids and changes in sulfation patterns by MS. Glucosuria.
• Biomarker : UPLC/MS showed increase in urinary levels of 6-hydroxymelatonin.
24
![Page 25: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/25.jpg)
Cisplatin in mice,
• Biomarker : Altered urinary levels of glucose, amino acids and Krebs cycle intermediates that preceded changes in serum creatinine.
Chronic toxicity testing of nephrotoxicants: gentamicin, cisplatin and tobramycin in SD rats, non targetted analysis after 1, 5 and 28 days dosing caused Aminoaciduria (marker of kidney damage) due to decreased renal reabsorption. 25
![Page 26: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/26.jpg)
Used in the drug development process
• Early drug development studies e.g. used in phase I study for
establishing doses and dosing regimen for future phase II studies.
• Safety studies e.g. APAP induced hepatotoxicity study• Proof of concept studies• Molecular profiling
26
![Page 27: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/27.jpg)
27
![Page 28: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/28.jpg)
28
![Page 29: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/29.jpg)
Clinical biomarker in Lung Cancer: Volumetric growth analysis of lesions in high resolution CT.
29
![Page 30: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/30.jpg)
30
![Page 31: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/31.jpg)
A new face in diagnostics, therapeutics & drug development.
Potential to encourage innovation, improve efficiency, save costs.
Potential to encourage innovation, improve efficiency, save costs, and gain research organizations a valuable advantage.
The ultimate promise of a future towards personalized healthcare.
31
![Page 32: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/32.jpg)
• Biomarkers in toxicology, Timbrell J. A., Volume 129, Issue 1, Pages 1-12, 7 August 1998.
• Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity, Beger R. D., Volume 243, Issue 2, Pages 154–166, March 2010.
• Biomarkers of Toxicity, NTP Workshop, Workshop report, September 20-21, 2006.
32
![Page 33: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/33.jpg)
• Clinical Biomarkers in drug discovery and development, Richard Frank and Richard Hargreaves, Volume 2, Pages 566-580, July 2003.
• Biomarkers and surrogate endpoints, Clinical research and applications, G. D. Downing, Elsevier (2000).
• Biomarkers in Drug Development – A CRO Perspective, John Allison & Steve Brooks, pages 15-19, 2004.
33
![Page 34: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/34.jpg)
34
![Page 35: Biomarkersintoxicologyandclinicalresearch 120726101025-phpapp01](https://reader036.vdocument.in/reader036/viewer/2022070318/557a9975d8b42aa6568b4aa5/html5/thumbnails/35.jpg)
35
DISCUSSION